SCHEMBL10127716

SCHEMBL10127716

Cc1ccc(NC(=O)OCc2ccccc2)cc1C1CCN(C2CCN(C)CC2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.46
BTK Q06187 2/20 0.45
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
ALDH1A1 P00352 1/20 0.44
TP53 P04637 1/20 0.44
MAPT P10636 1/20 0.44
TSHR P16473 1/20 0.44
ATM Q13315 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KCNA5 P22460 1/20 0.44
MGLL Q99685 1/20 0.43
BLK P51451 1/20 0.43
PSEN1 P49768 1/20 0.42
PSEN2 P49810 1/20 0.42
APH1B Q8WW43 1/20 0.42
NCSTN Q92542 1/20 0.42
APH1A Q96BI3 1/20 0.42
PSENEN Q9NZ42 1/20 0.42
BCHE P06276 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10127631 0.93 HRH3 (0.46) HRH3BTKNPC1RAB9AALDH1A1
SCHEMBL10127629 0.86 MGLL (0.51) HRH3BTKNPC1RAB9AALDH1A1
SCHEMBL4615788 0.85 BTK (0.50) HRH3BTKNPC1RAB9AALDH1A1
SCHEMBL10127713 0.85 MGLL (0.50) HRH3MGLLBCHE
SCHEMBL4615967 0.81 NAMPT (0.48) BTKNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4615264 0.81 NPC1 (0.50) NPC1RAB9AALDH1A1TP53MAPT
SCHEMBL27481407 0.79 HTR1D (0.68) BTKMAPT
SCHEMBL10127700 0.78 MGLL (0.56) HRH3MGLL
SCHEMBL4852743 0.77 HRH3 (0.44) HRH3NPC1RAB9AALDH1A1TP53
SCHEMBL2935082 0.76 HTR1D (0.61) BTKMAPTATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 HRH3 1242/4885BTK 1252/4885NPC1 3728/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 HRH3 1242/4885BTK 1252/4885NPC1 3728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.